Lara Robinson, MS

KOL Engagement + Insights Director @Celcuity •Advocate for patients + cancer research •Infinitely curious •Grateful Mom •Traveler •Lover of nature + animals.

[Celcuity @celcuity]

We are very pleased to announce that Celcuity has submitted its supplemental NDA to the FDA for REVTORPYK™ (gedatolisib. You can find more details in the press release: https://t.co/2CMkh3Gmbs
$CELC

[Celcuity @celcuity]

REVTORPYK™ (gedatolisib) in combination with fulvestrant, w/or/wo palbociclib, is recommended by the NCCN Clinical Practice Guidelines in Oncology as a preferred Category 1 second-line and/or subsequent-line therapy. Details in our press release: https://t.co/cIjr1i0Wq1 $CELC

[Celcuity @celcuity]

#NEWS: The FDA has approved our targeted therapy for patients with HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer following progression on prior therapy. Learn more: https://t.co/5CRq2e4wiO
#FDAApproval
#BreastCancer
$CELC

[Oncology Brothers @OncBrothers]

Gedatolisib is now @US_FDA ✅ based off VIKTORIA-1: PhIII, Gedato (PI3K/mTORi) + Fulv +/- Palbo vs. Fulv in HR+ after one line of ET in HR+

- mPFS: 9.3mos w/triplet vs. single agent Fulv (HR: 0.24)
- mPFS: 7.4mos w/doublet vs. single agent Fulv (HR: 0.33)
- AEs (IV/⏰ toxicity)

#OncTwitter #bcsm

[Celcuity @celcuity]

Celcuity reported detailed results for the PIK3CA mutant cohort of the pivotal Phase 3 VIKTORIA-1 trial in patients with HR+/HER2- advanced breast cancer. Read our press release here: https://t.co/8c8yIR8p5R

[Jason A. Mouabbi MD @JAMouabbi]

VIKTORIA-1 PIK3CA-mutant cohort (LBA1008) dropped this morning at #ASCO26.

Gedatolisib roughly doubled PFS vs alpelisib + fulvestrant after CDK4/6i progression:

• Geda doublet: 11.3 mo
• Geda triplet: 11.1 mo
• Alpelisib + fulv: 5.6 mo

ORR 48.9% (triplet) / 35.7% (doublet)

IMO Three things worth sitting with:

1️⃣ This beat an active comparator: Piqray, not fulvestrant alone. That’s a harder bar than the WT cohort cleared, and it makes the win more meaningful.

2️⃣ The doublet matched the triplet on PFS (11.3 vs 11.1). Palbociclib deepened responses (ORR 48.9 vs 35.7) but didn’t extend PFS in this readout. Might be beneficial to start with the triplet to increase the likelihood of a response and then transition to a maintenance doublet

3️⃣ The quiet headline is tolerability: hyperglycemia reported lower than anything in this class to date. That’s been the Achilles’ heel of PAM inhibition since SOLAR-1.

This is the first PAM inhibitor positioned to deliver regardless of PIK3CA status. BIG WIN 👏🏼👏🏼👏🏼

#bcsm

[Memphis Baseball @MemphisBaseball]

TIGERS ON 🔝

#GoTigersGo | @American_Conf

[Memphis Baseball @MemphisBaseball]

FOR THE PROGRAM 😤

#GoTigersGo | @ChickfilA

[OncoNexus @Onco_Nexus]

Late last week, Celcuity announced positive topline VIKTORIA-1 data in the PIK3CA-mutant cohort, with gedatolisib plus fulvestrant and palbociclib showing a clinically meaningful PFS improvement versus alpelisib plus fulvestrant. The update adds even more weight to this discussion as the post CDK4/6 HR+/HER2- breast cancer landscape continues to evolve.

Dr. @elmayermd & Dr. @mchayleh, discuss what clinicians need to watch as triplets, doublets, sequencing, toxicity, and biomarker driven strategies move closer to practice.

More updates coming post ASCO on From Podium to Practice highlighting Viktoria-1 & much more!

Full Discussion:
https://t.co/MJni1f4OBV

[Hope Rugo @hoperugo]

The only agent with positive data in wild type and mutant BC since everolimus! Caveats as noted. IV 3 out of 4 weeks and stomatitis. @OncoAlert

[Celcuity @celcuity]

Today, we announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with HR+/HER2- PIK3CA mutant advanced breast cancer. https://t.co/9iBrTNsRQm

[Memphis Baseball @MemphisBaseball]

Took care of business ‼️

#GoTigersGo | #MemphisRising

[Celcuity @celcuity]

We are proud to announce publication in the Journal of Clinical Oncology of results from the Phase 3 VIKTORIA-1 clinical trial. Read more here: https://t.co/5tT0Bm67OU $CELC #gedatolisib

[Susan G. Komen @SusanGKomen]

Today is #MetastaticBreastCancerDay, also called stage IV or advanced breast cancer. 🩷🩵

Learn more about MBC: https://t.co/31hSBujyka

[Oncology Brothers @OncBrothers]

Less than 2 months to #ASCO25! Join us to🗣️the current SoC➕how the data from #ASCO25 will change/reinforce our practice!

InPerson: May 31st, 2025
Location📍Marriott Marquis
Time: 6:30-9:00PM
Register https://t.co/w6VfiEEw4g

#AdvInOnc25 #bcsm #OncTwitter #gism #lcsm #gusm

[Memphis Baseball @MemphisBaseball]

C-Rob gets 'em looking to end B3 💪

E3 | MEM 2, OLE MISS 1

[Memphis Baseball @MemphisBaseball]

3️⃣⬆️3️⃣⬇️

@cadenrobinson17 retires the side in order in T1.

[Dr. Cathy Eng @CathyEngMD]

What a way to close @ASCO #ASCOGI25! Have an informal gathering of friends to celebrate everyone’s achievements! #promotions #leadership #research CONGRATS 👏 👏 @ParseghianC @VanMorrisMD @adasarimd with my forever friends Dr. David Fogelman and the AMAZING @LaraLRobinson. #grateful

[Christine Parseghian, MD @ParseghianC]

BREAKWATER Ph3 showing an incredible improvement in ORR by 21% and doubling of the duration of response with the addition of FOLFOX to enco+cetux in BRAFV600E MT CRC. 👏🏻🙌🏻 Congrats to my forever mentor @skopetz for changing the standard of care in 1L CRC!!#ASCOGI25 @FightCRC

[OncoAlert @OncoAlert]

Dear Colleagues
The OncoAlert🚨 Network along with our partners at
@ESSOnews @ESGO_society @CancerCareMASCC &
@SIOGorg invite you to the #OncoAlertColloquium

REGISTER for FREE HERE👉 https://t.co/zFzR5INxWx
February 3-9, 2025 💯% Virtual & Interactive

Watch Our #GI Faculty @CathyEngMD 🇺🇸 of Vanderbilt Health

Presenting on #ColorectalCancer and Anal #Cancer year in Review on February 6, 2025

Our Collaborators APCCC, ABC Global , GUARD Consortium , @mybsmo, GU Cast, KidneyCan

Huge thanks to our friend @ONCOassist and OncobitesTv

@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @heinrich_kat @NiuSanford

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK